Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
By R. Ozols, B. Bundy, B. Greer, J. Fowler, D. Clarke‐Pearson, R. Burger, Robert S. Mannel, K. Degeest, E. Hartenbach, R. Baergen. Journal of Clinical Oncology, 2003
2,032 citations recorded by the source corpus.
Subfields: Oncology, Reproductive Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/f308a217889aad3fec5769d16721e68b3ea4d37f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Reproductive Medicine
In Surgery
Citations in the corpus
- Recent Progress in the Diagnosis and Treatment of Ovarian Cancer (2011, methodology): “Pegylated liposomal doxorubicin and topotecan have been compared in a randomized phase 3 trial and showed similar response rates in patients with platinum-resistant disease, with no significant differences in response, PFS, or OS.94 Gemcitabine has been studied as a single agent in platinum-resistan”
- ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease (2019, result): “arm, the imbalance in PFS/OS benefit ratio and the low OS in the control group compared with published data [209, 210] further limit the clinical relevance and implementation of i.”